Wang et al. (2024) highlighted that for the treatment of MASH, priority consideration may be given to thiazolidinediones (TZDs), vitamin E combined with pioglitazone, glucagon-like peptide-1 (GLP-1) receptor agonists, and FGF-21 analogs. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.